改善基于细胞外囊泡的mRNA输送,用于家族性高胆固醇血症治疗
Zheng Yang1,2,3, Panpan Ji4, Zhelong Li5
1College of Otolaryngology, Head and Neck Surgery, Chinese PLA General Hospital, Beijing 100853, China.
Theranostics
|June 23, 2023
概括
这项研究开发了一种改进的细胞外囊泡 (EV) 策略,用于输送低密度脂蛋白受体 (LDLR) mRNA治疗家族性高胆固醇血症 (FH). 该方法增强了mRNA加载到EV中,并确保其在受体细胞中释放,以获得有效的基因治疗.
科学领域:
- 基因治疗 基因治疗
- 纳米医学是一种纳米医学.
- 分子生物学分子生物学
背景情况:
- 细胞外囊泡 (EVs) 显示出提供低密度脂蛋白受体 (LDLR) mRNA的潜力,以治疗家族性高胆固醇血症 (FH).
- 目前基于EV的mRNA传递面临着负载效率低下和受体细胞中RNA释放的挑战.
- 与EV蛋白结合的RNA结合蛋白 (RBPs) 改善了RNA封装,但阻碍了内分体逃逸.
研究的目的:
- 开发一种改进的策略,以有效地将LDLRmRNA封装到EV中.
- 从EV中获得可控的mRNA释放到受体细胞的细胞质中.
- 为了在体内评估这种增强的EV介导mRNA输送系统的治疗疗效.
主要方法:
- 工程化供体细胞以表达一种融合蛋白 (CD9-MCP),该蛋白与LDLRmRNA上的特定RNA吸收体结合.
- 同时处理受体细胞与含有LDLR mRNA的治疗性EV和携带"LDLR释放器"分子的EV.
- 向LDLR淘汰 (LDLR-/-) 小鼠施用联合EV,并通过尾静脉注射评估治疗效果.
主要成果:
- 通过MS2-MCP相互作用,证明了LDLRmRNA在EV中加载效率的提高.
- "LDLR释放器"竞争性地结合MS2体,促进LDLRmRNA释放用于翻译.
- 在受体肝细胞中LDLR表达的成功导致LDLR-/-小鼠的显著治疗益处.
结论:
- 开发了一种基于EV的新型mRNA输送策略,用于增强封装和控制释放.
- 这个系统有效地将治疗性mRNA传递给接受细胞,用于翻译和基因治疗.
- 这种方法在治疗家族性高胆固醇血症等遗传疾病方面具有重大潜力.
相关概念视频
Cholesterol: Significance and Regulation
605
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Considering cholesterol and...
605
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
706
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
706
Lipid Absorption
542
Dietary triglycerides from chyme in the duodenum are mixed with bile salts produced by the liver to emulsify fats. As a result, large droplets are broken down into smaller ones, increasing the surface area for enzymatic action. Once emulsified, pancreatic lipases hydrolyze the triglycerides into free fatty acids and monoglycerides.
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
542
Regulated mRNA Transport
6.3K
In eukaryotes, transcription and translation are compartmentalized; an mRNA is first synthesized in the nucleus and then selectively transported to the cytoplasm for protein synthesis. Before transport, a pre-mRNA undergoes several steps of post-transcriptional modifications including splicing, 5' capping, and the addition of a poly-adenine tail. Various proteins bind to the pre-mRNA during these modifications. The mRNA transport takes place with the help of multiple proteins playing...
6.3K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
204
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
204
Atherosclerosis III: Management
15
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
15


